- Email: [email protected]
P0088 Experience with higher doses of radiotherapy in the postoperative treatment of glioblastoma multiforme: A single institutional report
e34
Abstracts / 50 (2014) e1–e74
Interpretation: These data provide a baseline for further epidemiological studies. Our encouraging results in radiotherapy treatment of primary malignant tumours highlight the benefits of definitive or postoperative radiation.
http://dx.doi.org/10.1016/j.ejca.2014.03.131
P0088 EXPERIENCE WITH HIGHER DOSES OF RADIOTHERAPY IN THE POSTOPERATIVE TREATMENT OF GLIOBLASTOMA MULTIFORME: A SINGLE INSTITUTIONAL REPORT A. Sedighi Pashaki a, E. Akbari Hamed a,*, M. Abassi b, K. Mohamadian a, A. Maddah Safaei c, M.H. Gholami a. a Mahdieh Department of Radiation Oncology, Hamadan, Iran, b Hamadan University of Medical Sciences, Hamadan, Iran, c Tehran University of Medical Sciences, Tehran, Iran Background: Glioblastoma multiforme is a highly aggressive tumour with median survival of approximately 14 months. Management consists of maximal surgical resection followed by postoperative chemoradiation with concurrent then adjuvant temozolamide. The standard radiotherapy dose is 60 Gy in 2-Gy fractions. Most tumour recurrences occur within the previous irradiation field. Regimens designed to deliver higher radiation dose to improve local control and enhance survival warrant investigation. Methods: We report a single institutional experience of treatment of consecutive patients with glioblastoma multiforme, treated with resection, postoperative radiotherapy followed by concurrent and/or adjuvant chemotherapy. Findings: Of the 80 patients who entered the study, 68 completed the treatment course; there were 45 (66.2 %) male and 23 (33.8%) female patients with a mean age at diagnosis of 48.97 ± 12.85 (21–75) years. At a median follow up of 19 months, 39 (57.3%) patients had evidence of tumour progression and 36 (52.9%) patients had died. Median overall survival for all patients was 16 months and progression-free survival for all patients was 6.02 months. All potential prognostic factors were analysed to evaluate their effects on overall survival. age of 50 years or younger, concurrent and adjuvant chemotherapy, and extent of surgery were significant. We noted a lower progression rate among patients who received higher doses of radiotherapy (>60 Gy; p = 0.03). Overall survival was also increased, but this was not significant. Interpretation: This study suggests that higher radiation doses (>60 Gy) can improve local control and potentially survival; prospective multicentric studies should be done to evaluate the effect of higher doses of conformal radiation on the outcomes of patients with glioblastoma multiforme.
http://dx.doi.org/10.1016/j.ejca.2014.03.132
P0089 COMBINATION OF CURCUMOL WITH CELECOXIB SYNERGISTICALLY ENHANCES THEIR ANTI-MIGRATION EFFECTS VIA FAK/ERK/PI3K/AKT PATHWAYS IN HUMAN NONSMALL-LUNG CANCER CELLS
M.-H. Chen, Z.-C. Hua. Macau University of Science and Technology, State Key Laboratory of Quality Research in Chinese Medicine, Macau, China Background: Celecoxib, a COX-2 inhibitor, may be a potent chemopreventive agent for lung cancer. However, the long-term use of celecoxib is not safe and may be limited due to its serious side-effects. Methods: We examined the effect of curcumol, a common traditional Chinese medicine isolated from Rhizoma curcumae, on the inhibitory potential of celecoxib in human non-small-cell lung cancer cells. Findings: Our data suggest a synergistic interaction between curcumol and celecoxib in terms of lung cancer cell growth inhibition, without enhanced toxicity in normal human cells (HUVEC). The combination of curcumol and celecoxib was not able to close the wound area in a wound healing assay. Mediation of the enhanced inhibitory efficacy in lung cancer cells was achieved by reducing tumour cell migration and was closely associated with the deregulation of focal adhesion proteins (FAK), and phosphorylation of ERK and PI3K. Interpretation: These data demonstrate that combined medication involving curcumol and celecoxib could be effective for anti-migration in the treatment of lung cancer cells.
http://dx.doi.org/10.1016/j.ejca.2014.03.133
P0090 COMPARISON OF FINE NEEDLE ASPIRATION, TOUCH PRINT, AND CRUSH PRINT WITH PERMANENT PATHOLOGY IN THE DIAGNOSIS OF BREAST LUMPS IN IRANIAN PATIENTS M. Ahmadinejad a,*, A.A. Pour b, Z. Amiri c. a Department of Surgery, Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran, b Departmentof Pathology, Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran, c Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran Background: In addition to timaging and clinical examinations, fine needleaspiration (FNA) preoperatively together with Touch Print, Crush Print, and frozen section intraoperatively are used to reach a diagnosis for patients with a breast mass.In this study, in addition to documenting the epidemiologic and clinical characteristics of the disease, the results of intraoperative Crush Print and Touch Print were compared with permanent pathology. Methods: This cross-sectional study was done on 107 patients with breast masses, who had been referred to Shohada Hospital of Khorramabad in 2012. The epidemiological and clinical features of the patients were collected using a questionnaire. FNA was done preoperatively, and Touch Print and Crush Print were prepared intraoperatively and sent to the Pathology Ward. The results were compared with permanent pathology For all the methods, the diagnostic values of sensitivity, specificity, positive predictive value,negative predictive value, false positive percentage, and false negative percentage were calculated. Findings: For comparison of Touch Print and Crush Print with pathological diagnosis indetecting breast cancer, sensitivity, specificity,positive predictive value, negative predictive value, falsepositive percentage, and false negative percentage were 97.8%, 100%, 98.4%, 0%, and 2.2%. For the comparison of FNA with pathological diagnosis of breast cancer, these rates were 80.4%, 98%, 97.3%, 87.7%, 2%, and 19.6%, respectively.
Abstracts / 50 (2014) e1–e74
Interpretation: These data provide a baseline for further epidemiological studies. Our encouraging results in radiotherapy treatment of primary malignant tumours highlight the benefits of definitive or postoperative radiation.
http://dx.doi.org/10.1016/j.ejca.2014.03.131
P0088 EXPERIENCE WITH HIGHER DOSES OF RADIOTHERAPY IN THE POSTOPERATIVE TREATMENT OF GLIOBLASTOMA MULTIFORME: A SINGLE INSTITUTIONAL REPORT A. Sedighi Pashaki a, E. Akbari Hamed a,*, M. Abassi b, K. Mohamadian a, A. Maddah Safaei c, M.H. Gholami a. a Mahdieh Department of Radiation Oncology, Hamadan, Iran, b Hamadan University of Medical Sciences, Hamadan, Iran, c Tehran University of Medical Sciences, Tehran, Iran Background: Glioblastoma multiforme is a highly aggressive tumour with median survival of approximately 14 months. Management consists of maximal surgical resection followed by postoperative chemoradiation with concurrent then adjuvant temozolamide. The standard radiotherapy dose is 60 Gy in 2-Gy fractions. Most tumour recurrences occur within the previous irradiation field. Regimens designed to deliver higher radiation dose to improve local control and enhance survival warrant investigation. Methods: We report a single institutional experience of treatment of consecutive patients with glioblastoma multiforme, treated with resection, postoperative radiotherapy followed by concurrent and/or adjuvant chemotherapy. Findings: Of the 80 patients who entered the study, 68 completed the treatment course; there were 45 (66.2 %) male and 23 (33.8%) female patients with a mean age at diagnosis of 48.97 ± 12.85 (21–75) years. At a median follow up of 19 months, 39 (57.3%) patients had evidence of tumour progression and 36 (52.9%) patients had died. Median overall survival for all patients was 16 months and progression-free survival for all patients was 6.02 months. All potential prognostic factors were analysed to evaluate their effects on overall survival. age of 50 years or younger, concurrent and adjuvant chemotherapy, and extent of surgery were significant. We noted a lower progression rate among patients who received higher doses of radiotherapy (>60 Gy; p = 0.03). Overall survival was also increased, but this was not significant. Interpretation: This study suggests that higher radiation doses (>60 Gy) can improve local control and potentially survival; prospective multicentric studies should be done to evaluate the effect of higher doses of conformal radiation on the outcomes of patients with glioblastoma multiforme.
http://dx.doi.org/10.1016/j.ejca.2014.03.132
P0089 COMBINATION OF CURCUMOL WITH CELECOXIB SYNERGISTICALLY ENHANCES THEIR ANTI-MIGRATION EFFECTS VIA FAK/ERK/PI3K/AKT PATHWAYS IN HUMAN NONSMALL-LUNG CANCER CELLS
M.-H. Chen, Z.-C. Hua. Macau University of Science and Technology, State Key Laboratory of Quality Research in Chinese Medicine, Macau, China Background: Celecoxib, a COX-2 inhibitor, may be a potent chemopreventive agent for lung cancer. However, the long-term use of celecoxib is not safe and may be limited due to its serious side-effects. Methods: We examined the effect of curcumol, a common traditional Chinese medicine isolated from Rhizoma curcumae, on the inhibitory potential of celecoxib in human non-small-cell lung cancer cells. Findings: Our data suggest a synergistic interaction between curcumol and celecoxib in terms of lung cancer cell growth inhibition, without enhanced toxicity in normal human cells (HUVEC). The combination of curcumol and celecoxib was not able to close the wound area in a wound healing assay. Mediation of the enhanced inhibitory efficacy in lung cancer cells was achieved by reducing tumour cell migration and was closely associated with the deregulation of focal adhesion proteins (FAK), and phosphorylation of ERK and PI3K. Interpretation: These data demonstrate that combined medication involving curcumol and celecoxib could be effective for anti-migration in the treatment of lung cancer cells.
http://dx.doi.org/10.1016/j.ejca.2014.03.133
P0090 COMPARISON OF FINE NEEDLE ASPIRATION, TOUCH PRINT, AND CRUSH PRINT WITH PERMANENT PATHOLOGY IN THE DIAGNOSIS OF BREAST LUMPS IN IRANIAN PATIENTS M. Ahmadinejad a,*, A.A. Pour b, Z. Amiri c. a Department of Surgery, Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran, b Departmentof Pathology, Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran, c Lorestan University of Medical Sciences, Khorramabad, Lorestan, Iran Background: In addition to timaging and clinical examinations, fine needleaspiration (FNA) preoperatively together with Touch Print, Crush Print, and frozen section intraoperatively are used to reach a diagnosis for patients with a breast mass.In this study, in addition to documenting the epidemiologic and clinical characteristics of the disease, the results of intraoperative Crush Print and Touch Print were compared with permanent pathology. Methods: This cross-sectional study was done on 107 patients with breast masses, who had been referred to Shohada Hospital of Khorramabad in 2012. The epidemiological and clinical features of the patients were collected using a questionnaire. FNA was done preoperatively, and Touch Print and Crush Print were prepared intraoperatively and sent to the Pathology Ward. The results were compared with permanent pathology For all the methods, the diagnostic values of sensitivity, specificity, positive predictive value,negative predictive value, false positive percentage, and false negative percentage were calculated. Findings: For comparison of Touch Print and Crush Print with pathological diagnosis indetecting breast cancer, sensitivity, specificity,positive predictive value, negative predictive value, falsepositive percentage, and false negative percentage were 97.8%, 100%, 98.4%, 0%, and 2.2%. For the comparison of FNA with pathological diagnosis of breast cancer, these rates were 80.4%, 98%, 97.3%, 87.7%, 2%, and 19.6%, respectively.